Tralokinumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | IL13 |
| Clinical data | |
| Legal status | ? |
| Identifiers | |
| CAS number | 1044515-88-9  |
| ATC code | None |
| Chemical data | |
| Formula | C6374H9822N1698O2014S44 |
| Mol. mass | 143.87 kDa |
| (what is this?) (verify) | |
Tralokinumab is a human monoclonal antibody which targets the cytokine interleukin 13,[1] and is designed for the treatment of asthma and inflammatory diseases.[2]
Tralokinumab was discovered by Cambridge Antibody Technology as CAT-354[3] who took it through pre-clinical development.[4] As of April 2012 it is being developed by MedImmune.[5][6]
Discovery and Development
Tralokinumab was optimised by Cambridge Antibody Technology scientists using Ribosome Display.[7]
In March 2008, MedImmune LLC initiated a study to assess bioavailability and pharmacokinetics of CAT-354.[8]
On 21 July 2011, MedImmune LLC initiated a phase IIb, randomized, double-blind Study to evaluate the efficacy of Tralokinumab in adults with asthma.[9]
On 29 November 2011, AstraZeneca and MedImmune Ltd announced their intention to start a phase II trail to evaluate the efficacy and safety of Tralokinumab in patients with active, moderate-to-severe ulcerative colitis.[10]
References
- ↑ Kopf, Manfred; Bachmann, Martin F.; Marsland, Benjamin J. (2010). "Averting inflammation by targeting the cytokine environment". Nature Reviews Drug Discovery 9 (9): 703–18. doi:10.1038/nrd2805. PMID 20811382.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Tralokinumab". American Medical Association.
- ↑ Douthwaite, J.A.; Groves, M.A.; Dufner, P.; Jermutus, L. (2005). "An improved method for an efficient and easily accessible eukaryotic ribosome display technology". Protein Engineering Design and Selection 19 (2): 85–90. doi:10.1093/protein/gzj003. PMID 16368721.
- ↑ May, RD; Monk, PD; Cohen, ES; Manuel, D; Dempsey, F; Davis, NHE; Dodd, AJ; Corkill, DJ et al. (2012). "Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma". British Journal of Pharmacology 166 (1): 177–193. doi:10.1111/j.1476-5381.2011.01659.x. PMID 21895629.
- ↑ "Pipeline". MedImmune. Retrieved 11 June 2013.
- ↑ "Studies found for CAT-354". ClinicalTrials.gov. Retrieved 11 June 2013.
- ↑ Thom, George; Minter, Ralph (2012). Optimization of CAT-354, a Therapeutic Antibody Directed Against Interleukin-13, Using Ribosome Display. "Ribosome Display and Related Technologies". Methods in Molecular Biology. Methods in Molecular Biology 805: 393–401. doi:10.1007/978-1-61779-379-0_22. ISBN 978-1-61779-378-3. PMID 22094818.
- ↑ ClinicalTrials.gov NCT00638989 A Study to Assess Bioavailability and Pharmacokinetics of CAT 354
- ↑ ClinicalTrials.gov NCT01402986 A Phase 2b, Randomized, Double-blind Study to Evaluate the Efficacy of Tralokinumab in Adults With Asthma
- ↑ ClinicalTrials.gov NCT01482884 Evaluation of Efficacy and Safety of Tralokinumab in Patients With Active, Moderate-to-severe Ulcerative Colitis